Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Checking expectations
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-29 13:21:51.324434.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valeant Pharmaceuticals International (NYSE: VRX) is expected to report Q4 earnings on Feb. 28. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Valeant Pharmaceuticals International's revenues will grow 37.8% and EPS will grow 28.7%.
The average estimate for revenue is $948.4 million. On the bottom line, the average EPS estimate is $1.21.
Revenue details
Last quarter, Valeant Pharmaceuticals International reported revenue of $884.1 million. GAAP reported sales were 47% higher than the prior-year quarter's $600.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $1.15. GAAP EPS of $0.02 for Q3 were 85% lower than the prior-year quarter's $0.13 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 74.0%, 160 basis points better than the prior-year quarter. Operating margin was 25.8%, 170 basis points better than the prior-year quarter. Net margin was 0.9%, 590 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $3.50 billion. The average EPS estimate is $4.41.
Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 194 members out of 219 rating the stock outperform, and 25 members rating it underperform. Among 74 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 67 give Valeant Pharmaceuticals International a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Valeant Pharmaceuticals International is outperform, with an average price target of $65.38.